Botulinum toxin may improve quality of life in hidradenitis suppurativa
Click Here to Manage Email Alerts
Botulinum toxin can help improve the quality of life in patients with hidradenitis suppurativa, according to a study.
A single-center, randomized, double-blind trial enrolled 20 patients with HS disease stage I to III. Subjects received injections of either botulinum toxin (BTX-B) (NeuroBloc, Eisai) or saline placebo.
In the BTX-B group, Dermatology Life Quality Index scores improved from a median of 17 to 8 after 3 months, while those in the placebo group had an improvement from 13.5 to 11 (P < .05).
HS impairment of general health, as rated by the patients on the visual analog scale, improved from a baseline median of 8 to 3.5 after BTX treatment compared with a change from a median of 6 to 5.5 in the placebo group (P < .05).
The number of total lesions was reduced from baseline in the treatment group, but the difference compared with the placebo group was not significant.
“In our study, treatment with BTX-B improved the QoL in patients with HS, which could be explained by a reduction in total lesions,” the study authors wrote.
The study also found 55% of the population had hyperhidrosis, which is a significant difference from the general population, with a prevalence of approximately 3%.
“The current study supports the association between hyperhidrosis and HS,” the authors wrote. “If increased eccrine sweating occurs in HS individuals in general, the idea of using BTX-B is even more logical.”
Collapse
Read more about
Click Here to Manage Email Alerts